With economic prosperity, political stability and significant growth prospects, Canada has much to admire. However, despite a universal healthcare system, Canadians still lack universal drug coverage and have the second highest out-of-pocket spending on drugs globally, behind only the United States.
Additionally, in what is the world’s tenth largest pharmaceutical market and home to a number of historic medical breakthroughs, Canadian health innovation has lagged behind not just that of its American neighbors to the south but also increasingly to several countries in Europe.
Designed for pharmaceutical executives with global strategies, this report explores solutions being explored to remedy discrepancies. On the innovation side this includes state R&D investment initiatives, the associations calling for increased and more productive inter-stakeholder dialogue, and the new strategies of the major global players implanted in Canada.
Also featured are movers and shakers among Canada’s broad spectrum of local companies; from generics manufacturers to biotechs and service providers, whose work is helping the nation regain its place at the top table of global healthcare and life sciences.
This report also examines the pharmaceutical value chain in which Canada is making a name for itself — stepping out of the shadows of the United States and developing a truly global reputation, including the clinical trials and contract research space, biotech, genomics and medical device manufacturing. Most eye-catchingly, Canada is forging ahead in new areas such as cannabinoid-based treatments, covered in depth in a special feature on medical cannabis.